Hepatocellular carcinoma: signaling pathways and therapeutic advances

Signal Transduction and Targeted Therapy, Год журнала: 2025, Номер 10(1)

Опубликована: Фев. 6, 2025

Abstract Liver cancer represents a major global health concern, with projections indicating that the number of new cases could surpass 1 million annually by 2025. Hepatocellular carcinoma (HCC) constitutes around 90% liver and is primarily linked to factors incluidng aflatoxin, hepatitis B (HBV) C (HCV), metabolic disorders. There are no obvious symptoms in early stage HCC, which often leads delays diagnosis. Therefore, HCC patients usually present tumors advanced incurable stages. Several signaling pathways dis-regulated cause uncontrolled cell propagation, metastasis, recurrence HCC. Beyond frequently altered therapeutically targeted receptor tyrosine kinase (RTK) involved differentiation, telomere regulation, epigenetic modification stress response also provide therapeutic potential. Investigating key their inhibitors pivotal for achieving advancements management At present, primary approaches (TKI), immune checkpoint (ICI), combination regimens. New trials investigating therapies involving ICIs TKIs or anti-VEGF (endothelial growth factor) therapies, as well combinations two immunotherapy The outcomes these expected revolutionize across all Here, we here comprehensive review cellular pathways, potential, evidence derived from late-stage clinical discuss concepts underlying earlier trials, biomarker identification, development more effective therapeutics

Язык: Английский

---

Progress of ADAM17 in Fibrosis‐Related Diseases

Mediators of Inflammation, Год журнала: 2025, Номер 2025(1)

Опубликована: Янв. 1, 2025

Fibrosis leads to structural damage and functional decline is characterized by an accumulation of fibrous connective tissue a reduction in parenchymal cells. Because its extremely poor prognosis, organ fibrosis poses significant economic burden. In order prevent treat more effectively, potential mechanisms need be investigated. A disintegrin metalloprotease 17 (ADAM17) membrane‐bound protein. It regulates intracellular signaling membrane protein degradation. mediated ADAM17 has been identified as important contributor, although the specific relationship between multiple regulatory functions pathogenesis unclear. This article describes activation, function, regulation, well role injury kidney, liver, heart, lung, skin, endometrium, retina. To develop new therapeutic approaches based on related signal pathways.

Язык: Английский

---

ZLDI-8 facilitates pexophagy by ROS-mediated activation of TFEB and ATM in HeLa cells

Bioorganic & Medicinal Chemistry Letters, Год журнала: 2025, Номер unknown, С. 130130 - 130130

Опубликована: Фев. 1, 2025

Язык: Английский

---

Polygonum multiflorum Stilbene Glycoside Oligomers induce the ferroptosis of triple negative breast cancer cells

BMC Cancer, Год журнала: 2025, Номер 25(1)

Опубликована: Апрель 14, 2025

The quality control testing component and main active ingredient of Polygonum multiflorum Thunb. (P. multiflorum), known as trans-2,3,5,4'-tetrahydroxystilbene 2-O-β-D-glucopyranoside (TSG), exhibits diverse biological activities. In this study, we report, for the first time, potent ability TSG to induce ferroptosis in triple negative breast cancer (TNBC) cell lines inhibit proliferation TNBC cells. Treatment with triggers production lipid peroxides, 4-hydroxynonenal (4-HNE), reactive oxygen species (ROS) cells, indicating induction ferroptosis. Both vivo vitro experiments confirmed inhibitory effects on metastasis. Furthermore, investigated other stilbene glycoside oligomers, alongside TSG, lines. These compounds also demonstrated suppress cells' findings suggest that by related could potentially serve a promising therapeutic strategy treatment.

Язык: Английский

---

Current research of the Notch pathway in hepatocellular carcinoma

European journal of medical research, Год журнала: 2025, Номер 30(1)

Опубликована: Май 20, 2025

Язык: Английский

---

Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies

Biomolecules, Год журнала: 2024, Номер 14(12), С. 1581 - 1581

Опубликована: Дек. 11, 2024

Immunotherapy has shown significant improvement in the survival of patients with hepatocellular carcinoma (HCC) compared to TKIs as first-line treatment. Unfortunately, approximately 30% HCC exhibits intrinsic resistance ICIs, making new therapeutic combinations urgently needed. The dysregulation Notch signaling pathway observed can affect immune cell response, reducing efficacy cancer immunotherapy. Here, we provide an overview how regulates responses and present rationale for combining inhibition ICIs improve Moreover, propose using exosomes non-invasive tools assess activation hepatic cells, enabling accurate stratification who benefit from combined strategies.

Язык: Английский

---

Notch signaling in digestive system cancers: Roles and therapeutic prospects

Cellular Signalling, Год журнала: 2024, Номер unknown, С. 111476 - 111476

Опубликована: Окт. 1, 2024

Язык: Английский

---

Effect and mechanism of novel HDAC inhibitor ZDLT-1 in colorectal cancer by regulating apoptosis and inflammation

International Immunopharmacology, Год журнала: 2024, Номер 143, С. 113333 - 113333

Опубликована: Окт. 9, 2024

Язык: Английский

---